相关实验视频
Updated: Jan 13, 2026

09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
7.9K
抗凝固疗法和微RNA在心力衰竭中的作用
Lucia Spartano1, Maria Lombardi1, Chiara Foglieni1
1Cardiovascular Research Center, IRCCS San Raffaele Hospital, 20132 Milan, Italy.
Biomolecules
|October 29, 2025
概括
微RNAs (miRs) 影响抗凝药在心力衰竭 (HF) 患者中的作用. 了解这些miR可以帮助个性化治疗,提高疗效和减少副作用,从而改善患者的治疗结果.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是导致死亡的主要原因,抗凝固剂经常用于预防血栓栓塞.
- 耐药性和对抗凝血剂的可变反应在HF管理中提出了重大挑战.
- 非编码RNAs,特别是microRNAs (miRs),正在成为HF中药物疗效的关键调节器.
研究的目的:
- 探索微RNAs (miRs) 在调节心力衰竭 (HF) 患者抗凝固药疗法的疗效方面的作用.
- 突出miRs作为预测生物标志物和治疗点的潜力,用于个人化高频抗凝治疗.
主要方法:
- 对最近研究的综述,研究了特定miRs与对各种抗凝固药物 (克洛皮多格雷尔,阿司匹林,华法林,NOACs) 的耐药性之间的联系.
- 在HF的背景下,检查miR表达,心脏重塑和凝血调节之间的联系.
- 对digoxin对miR-132的影响及其对高频率的影响的分析.
主要成果:
- 特定的miRs (例如miR-223,miR-26a,miR-19b-1-5p,miR-92a,miR-133,miR-137) 与抗克洛皮多格雷尔,阿司匹林和华法林的耐药性有关.
- 迪戈辛治疗可提高miR-132的调节,这与HF相关的心脏变化有关.
- 越来越多的证据将miR表达与新型口服抗凝剂 (NOAC) 和心脏重塑的药理学联系起来.
结论:
- 微RNA在心力衰竭中对抗凝血剂疗法的疗效和反应中发挥着重要作用.
- 利用对miR-药物相互作用的知识,可以在高频中开发个性化的抗凝策略.
- 对miRs的进一步研究有望改善高频率患者的治疗结果和患者生活质量.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Myocarditis III: Medical Management
168
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Cardiomyopathy V: Interprofessional Care
331
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
331

